Evidence map›Paper›PMID 31263729›Full record

ArticleOpen forum infectious diseases2019

Validation of a Novel Multivariate Method of Defining HIV-Associated Cognitive Impairment.

Jonathan Underwood, Davide De Francesco, James H Cole, Matthan W A Caan, Rosan A van Zoest, Ben A Schmand, David J Sharp, Caroline A Sabin, Peter Reiss, Alan Winston and 1 more

Abstract read
In one paragraph

Article in Open forum infectious diseases, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed.

  1. HIV-1 gp120-induced lysosomal stress responses are controlled by TRPML1 redox sensors.Redox report : communications in free radical research · 2026
    Article
  2. Article
  3. Article
  4. Infectious Diseases.Advances in neurobiology · 2024
    Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Jonathan UnderwoodDivision of Infectious Diseases, Imperial College London, UK.ORCID 0000-0001-6963-2821
Davide De FrancescoDepartment of Infection and Population Health, University College London, UK.ORCID 0000-0002-6185-0514
James H ColeDivision of Brain Sciences, Imperial College London, UK.
Matthan W A CaanDepartment of Radiology and Nuclear Medicine, Academic Medical Center, Amsterdam, The Netherlands.
Rosan A van ZoestDepartments of Global Health and Internal Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Infection and Immunity Institute, and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam, The Netherlands.
Ben A SchmandDepartment of Medical Psychology, Academic Medical Center, Amsterdam, The Netherlands.
David J SharpDivision of Brain Sciences, Imperial College London, UK.
Caroline A SabinDepartment of Infection and Population Health, University College London, UK.
Peter ReissDepartments of Global Health and Internal Medicine, Amsterdam University Medical Centers, University of Amsterdam, Amsterdam Infection and Immunity Institute, and Amsterdam Institute for Global Health and Development (AIGHD), Amsterdam, The Netherlands.
Alan WinstonDivision of Infectious Diseases, Imperial College London, UK.
COmorBidity in Relation to AIDS (COBRA) Collaboration and the Pharmacokinetic and clinical Observations in PePle over fiftY (POPPY) Study Group

Funding

CNS HIV ANTI-RETROVIRAL THERAPY EFFECTS RESEARCH /CHARTER/ -278022005-278022005N01MH022005 · NIMH · UNIVERSITY OF CA -SAN DIEGO · PI GRANT, IGOR · 2003 to 2006
–
Department of Health NIHR-RP-011-048Medical Research Council MR/M004236/1NIMH NIH HHS HHSN271201000030CNIMH NIH HHS HHSN271201000036CNIMH NIH HHS N01 MH022005Wellcome Trust
6 · The paper itself

Abstract

backgroundThe optimum method of defining cognitive impairment in virally suppressed people living with HIV is unknown. We evaluated the relationships between cognitive impairment, including using a novel multivariate method (NMM), patient- reported outcome measures (PROMs), and neuroimaging markers of brain structure across 3 cohorts.

methodsDifferences in the prevalence of cognitive impairment, PROMs, and neuroimaging data from the COBRA, CHARTER, and POPPY cohorts (total n = 908) were determined between HIV-positive participants with and without cognitive impairment defined using the HIV-associated neurocognitive disorders (HAND), global deficit score (GDS), and NMM criteria.

resultsThe prevalence of cognitive impairment varied by up to 27% between methods used to define impairment (eg, 48% for HAND vs 21% for NMM in the CHARTER study). Associations between objective cognitive impairment and subjective cognitive complaints generally were weak. Physical and mental health summary scores (SF-36) were lowest for NMM-defined impairment (

conclusionDifferent methods of defining cognitive impairment identify different people with varying symptomatology and measures of brain injury. Overall, NMM-defined impairment was associated with most neuroimaging abnormalities and poorer self-reported health status. This may be due to the statistical advantage of using a multivariate approach.

Indexed as

cognitive impairmentHIVmultivariateneuroimaging

Identifiers

PMID31263729
PMCPMC6590980

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.